Welcome to the Stocktwits Top 25 Newsletter this week!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

Here are the Stocktwits Top 25 Lists for this week:

The Top 25 list's Top Dawg was $ACLX ( ▼ 0.08% ) , climbing 77%!

$GILD ( ▲ 3.6% ) has entered a definitive agreement to acquire Arcellx for $115 per share in a deal valued at $7.8 billion. The move centers on securing anito-cel, a promising CAR T-cell therapy for multiple myeloma, to aggressively scale Gilead’s oncology footprint.

The $7.8 billion valuation represents a significant premium for $ACLX, which includes a $5-per-share contingent value right on top of the cash consideration. While the stock has traded near its $114.26 52-week high following the news, the acquisition price sits just above the analyst consensus average of $112.47, triggering a wave of neutral downgrades from firms like Stifel and Truist as the stock reaches its buyout ceiling.

Gilead aims to integrate Arcellx’s cell therapy platform. The deal effectively neutralizes recent technical bearishness—where shares were trading below their 20-day and 100-day SMAs—by providing a hard floor for investors near the $115.00 key resistance level.

Help us deliver the best content possible by completing this brief survey. 📝

Want to see some change? Email Kevin Travers your feedback; follow him on Stocktwits.

Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍

Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋